Your browser doesn't support javascript.
loading
節目: 20 | 50 | 100
结果 1 - 2 de 2
过滤器
添加過濾器








年份範圍
1.
Braz. j. infect. dis ; Braz. j. infect. dis;23(2): 130-133, Mar.-Apr. 2019. graf
文章 在 英语 | LILACS | ID: biblio-1039224

摘要

ABSTRACT Rifampicin is used in both phases of treatment for tuberculosis. In chronic use, the short half-life and the self-induction of metabolism can decrease the levels of the drug below the minimal inhibitory concentration. The aim of the study was to investigate whether plasma concentrations of rifampicin are sustained above 0.5 µg/mL in patients with tuberculosis using 600 mg/day. Rifampicin was measured in plasma by high-performance liquid chromatography and a sputum smear microscopy was performed in all days of the study. A total of 44 male patients completed the study. On days 31, 61 and 91, the mean plasma concentrations of rifampicin were 0.6 (0.5) µg/mL, 0.55 (0.5) µg/mL and 0.46 (0.4) µg/mL. There was a high variation of rifampicin levels leading to a high percentage of samples with concentrations below 0.5 µg/mL. There was no significant association between the frequency of samples with drug levels below 0.5 µg/mL with the conversion of the sputum microscopy. These data suggest that pre-doses samples offer limited information on the exposure of M. tuberculosis to rifampicin.


Subject(s)
Humans , Male , Adult , Middle Aged , Young Adult , Rifampin/administration & dosage , Rifampin/blood , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/blood , Antibiotics, Antitubercular/administration & dosage , Antibiotics, Antitubercular/blood , Reference Values , Sputum/drug effects , Sputum/microbiology , Microbial Sensitivity Tests , Prospective Studies , Reproducibility of Results , Chromatography, High Pressure Liquid , Treatment Outcome , Dose-Response Relationship, Drug , Mycobacterium tuberculosis/drug effects
搜索明细